Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Ovid Therapeutics Inc.NASDAQ: OVID
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$338.7M, compared with -$314.53M a year earlier.
Context
- Retained earnings amounted to 150.1% of total assets at the end of Q1 FY2026, down 235.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -7.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (321.71M) USD
- Year-over-year change
- -5.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (321.71M) | -5.7% |
| FY2024 | 2024-12-31 | (304.3M) | -9.5% |
| FY2023 | 2023-12-31 | (277.87M) | -23.2% |
| FY2022 | 2022-12-31 | (225.53M) | -31.6% |
| FY2021 | 2021-12-31 | (171.36M) | — |
Retained Earnings vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's Mar 2026 retained earnings of -$338.7M is the highest of the 11 companies compared; the peer median is -$779.75M.
- Its year-over-year change of -7.7% is the 2nd highest of 11, against a peer median of -19.7%.
- Retained earnings amounts to 150.1% of total assets for OVID, versus a peer median of 223.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$338.7M | -7.7% | — | 150.1% | |
| Mar 2026 | -$383.58M | -34.6% | — | 145.8% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | -$400.33M | -28.0% | — | 159.9% |
| Mar 2026 | -$473.84M | -32.7% | — | 216.0% | |
| Mar 2026 | -$547.72M | -44.9% | — | 123.6% | |
| Mar 2026 | -$759.15M | +8.0% | — | 382.5% | |
| Jun 2026 | -$800.35M | -23.0% | — | 170.1% | |
| Mar 2026 | -$862.54M | -16.2% | — | 352.6% | |
| Mar 2026 | -$1.35B | -15.7% | — | 231.7% | |
| Mar 2026 | -$1.49B | -16.4% | — | 521.7% | |
| Mar 2026 | -$4.72B | -14.8% | — | 364.0% | |
| Peer median (excluding OVID) | -$779.75M | -19.7% | — | 223.9% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M |
| Short-term Investments | 0 | 84.13M | 78.79M | 26.77M | 56.48M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.68M | 1 | 1K | 0 | 20.81M |
| Total Current Assets | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M |
| Property, Plant & Equipment (Net) | 242.76K | 16.07M | 14.66M | 13.23M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 164K | 222.1K | 200K | 92K | 0 |
| Long-term Investments | 3.56M | 5.62M | 17.63M | 20.97M | 64.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 96.13K | 1.97M | 1.94M | 1.93M | (4.22M) |
| Total Non-current Assets | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M |
| Total Assets | 194.54M | 155.27M | 144.03M | 92.17M | 150.93M |
| Account Payables | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.91M | 0 | 0 | 1K | 0 |
| Total Current Liabilities | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1 | 30M | 0 | 0 |
| Total Non-current Liabilities | 0 | 16M | 44.76M | 13.42M | 11.99M |
| Total Liabilities | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M |
| Common Stock | 70.36K | 70.47K | 71K | 71K | 130K |
| Retained Earnings | (171.36M) | (225.53M) | (277.87M) | (304.3M) | (321.71M) |
| Accumulated OCI | 0 | (42.19K) | 0 | (35K) | (202K) |
| Other Stockholders Equity | 0 | (1) | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M |
| Total Debt | 0 | 16.54M | 16M | 14.76M | 13.42M |
| Net Debt | (187.8M) | (28.33M) | (11.04M) | (11.55M) | 266K |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.